Concepedia

Author

Tinne Verhulst

Janssen (Belgium)

Also Known As

T. Verhulst, Tinne Verhulst, Verhulst T

45

Publications

602

Citations

9

H-Index

15

Concepts

All Affiliations

Janssen (Belgium)Janssen (United States)SpringhouseUniversity Medical Center GroningenUniversity of Groningen
TV

About

Tinne Verhulst is an author at Janssen (Belgium) specializing in cancer research, tumor biology, and epigenetic regulation.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

31

2

Cell Biology

2

2

31

3

Pharmacology

2

2

31

4

Cancer Cell Biology

1

1

11

5

Cancer Genetics

1

1

11

Tinne Verhulst

×

9

Publications

561

Citations

9

H-Index

YearCitations

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Timothy Perera, Eleonora Jovcheva, Laurence Mévellec,

Molecular Cancer Therapeutics

2017

335

Inhibition of Histone Deacetylases by Chlamydocin Induces Apoptosis and Proteasome-Mediated Degradation of Survivin

Stefanie De Schepper, Hélène Bruwiere, Tinne Verhulst,

Journal of Pharmacology and Experimental Therapeutics

2003

81

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in <i>KMT2A</i>- and <i>NPM1</i>-altered leukemias

Min Chul Kwon, Jan Willem Thuring, Olivier Querolle,

Blood

2024

48

Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-&amp;alpha;-positive breast cancer

Kate Sasser, Tineke Casneuf, Amy Axel,

Breast Cancer Targets and Therapy

2016

27

Abstract DDT02-04: A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models

Dirk Brehmer, Tongfei Wu, Geert Mannens,

Cancer Research

2017

20

Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia

Min Chul Kwon, Olivier Querolle, Xuedong Dai,

Blood

2022

16

Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-&alpha;-positive breast cancer

Tineke Casneuf, Axel AE, J. Álvarez,

SHILAP Revista de lepidopterología

2016

12

Abstract 950: In vivo efficacy and pharmacodynamic modulation of JNJ-64619178, a selective PRMT5 inhibitor, in human lung and hematologic preclinical models

Hillary J. Millar, Dirk Brehmer, Tinne Verhulst,

Cancer Research

2019

11

A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib

Elena M. Tosca, Nadia Terranova, Kim Stuyckens,

Cancer Chemotherapy and Pharmacology

2021

11

Page 1